[144] Jazz Pharmaceuticals, Inc. SEC Filing
Jazz Pharmaceuticals filed a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The shares represent restricted stock that vested on 08/07/2025 and were acquired as compensation. The filer intends to sell the shares on or about 08/08/2025 on NASDAQ through ETRADE FINANCIAL CORPORATION. The company shows 60,658,809 shares outstanding and reports Nothing to Report for securities sold in the past three months. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information about the issuer.
Jazz Pharmaceuticals ha depositato un Form 144 segnalando la proposta di vendita di 3,731 azioni ordinarie per un valore di mercato complessivo di $417,872. Le azioni sono titoli soggetti a restrizioni che sono diventati definitivi il 08/07/2025 e sono stati acquisiti come compenso. Il dichiarante intende vendere le azioni il o intorno al 08/08/2025 sul NASDAQ tramite ETRADE FINANCIAL CORPORATION. La societ脿 indica di avere 60,658,809 azioni in circolazione e riporta Niente da segnalare per i titoli venduti negli ultimi tre mesi. L鈥檃vviso include la dichiarazione standard che il venditore non 猫 a conoscenza di alcuna informazione materiale sfavorevole non divulgata riguardante l鈥檈mittente.
Jazz Pharmaceuticals present贸 un Form 144 informando sobre una propuesta de venta de 3,731 acciones ordinarias con un valor de mercado agregado de $417,872. Las acciones son t铆tulos restringidos que se consolidaron el 08/07/2025 y fueron adquiridas como 肠辞尘辫别苍蝉补肠颈贸苍. El declarante tiene la intenci贸n de vender las acciones en o alrededor del 08/08/2025 en el NASDAQ a trav茅s de ETRADE FINANCIAL CORPORATION. La compa帽铆a muestra 60,658,809 acciones en circulaci贸n e informa 'Nothing to Report' respecto a valores vendidos en los 煤ltimos tres meses. El aviso incluye la declaraci贸n est谩ndar de que el vendedor desconoce cualquier informaci贸n material adversa no divulgada sobre el emisor.
Jazz Pharmaceuticals電� 鞝滌晥霅� 毵り皝鞚� 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 3,731欤检潣 氤错喌欤茧ゼ 齑� 鞁滉皜 $417,872鞐� 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 08/07/2025鞐� 甓岆Μ臧� 頇曥爼霅� 鞝滍暅攵� 欤检嫕(restricted stock)鞙茧 氤挫儊鞙茧 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖鞛愲姅 頃措嫻 欤检嫕鞚� 08/08/2025瓴� NASDAQ鞐愳劀 ETRADE FINANCIAL CORPORATION鞚� 韱淀暣 毵り皝頃� 瓿勴殟鞛呺媹雼�. 須岇偓電� 60,658,809欤检潣 氚滍枆欤检嫕鞚� 氤搓碃頃橂┌ 歆�雮� 3臧滌洈臧� 毵る弰霅� 歃濌秾鞐� 甏�頃挫劀電� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 旮办灛頄堨姷雼堧嫟. 韱奠鞐愲姅 毵る弰鞚胳澊 氚滍枆須岇偓鞐� 甏�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Jazz Pharmaceuticals a d茅pos茅 un Form 144 d茅clarant la vente propos茅e de 3,731 actions ordinaires pour une valeur marchande totale de $417,872. Les actions repr茅sentent des titres restreints qui sont devenus acquis le 08/07/2025 et ont 茅t茅 re莽us en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅posant a l'intention de vendre les actions aux alentours du 08/08/2025 sur le NASDAQ via ETRADE FINANCIAL CORPORATION. La soci茅t茅 d茅clare 60,658,809 actions en circulation et indique 'Nothing to Report' pour les titres vendus au cours des trois derniers mois. L'avis inclut la mention standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable mat茅rielle non divulgu茅e concernant l'茅metteur.
Jazz Pharmaceuticals reichte ein Form 144 ein und meldete den geplanten Verkauf von 3,731 Stammaktien mit einem gesamten Marktwert von $417,872. Die Aktien sind eingeschr盲nkte Aktien, die am 08/07/2025 unverfallbar geworden sind und als 痴别谤驳眉迟耻苍驳 erworben wurden. Der Einreicher beabsichtigt, die Aktien am oder um den 08/08/2025 an der NASDAQ 眉产别谤 ETRADE FINANCIAL CORPORATION zu ver盲u脽ern. Das Unternehmen gibt 60,658,809 ausstehende Aktien an und meldet 'Nothing to Report' f眉r in den letzten drei Monaten verkaufte Wertpapiere. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegte, wesentliche nachteilige Information 眉产别谤 den Emittenten bekannt ist.
- None.
- None.
Insights
TL;DR: Routine sale of vested restricted stock; transaction size is immaterial to capitalization and likely neutral for investors.
The filing documents a proposed open-market sale of 3,731 common shares valued at $417,872, acquired the day before by restricted stock vesting. Relative to 60,658,809 shares outstanding, this amount is de minimis, so the direct impact on supply, market float, and share price is likely negligible. The use of a retail broker (ETRADE FINANCIAL CORPORATION) and the absence of other sales in the prior three months suggest this is a one-off disposition tied to compensation rather than a broader insider liquidity event.
TL;DR: Filing follows standard Rule 144 procedures; disclosure and seller representations are present and complete for the information provided.
The notice specifies acquisition by restricted stock vesting and lists payment as compensation, which clarifies the economic basis of the shares offered for sale. The form includes the required representation that the seller is not aware of undisclosed material adverse information. No other sales in the last three months are reported, which simplifies aggregation considerations under Rule 144. Based only on stated facts, the filing appears procedurally compliant and non-material to governance or capital structure.
Jazz Pharmaceuticals ha depositato un Form 144 segnalando la proposta di vendita di 3,731 azioni ordinarie per un valore di mercato complessivo di $417,872. Le azioni sono titoli soggetti a restrizioni che sono diventati definitivi il 08/07/2025 e sono stati acquisiti come compenso. Il dichiarante intende vendere le azioni il o intorno al 08/08/2025 sul NASDAQ tramite ETRADE FINANCIAL CORPORATION. La societ脿 indica di avere 60,658,809 azioni in circolazione e riporta Niente da segnalare per i titoli venduti negli ultimi tre mesi. L鈥檃vviso include la dichiarazione standard che il venditore non 猫 a conoscenza di alcuna informazione materiale sfavorevole non divulgata riguardante l鈥檈mittente.
Jazz Pharmaceuticals present贸 un Form 144 informando sobre una propuesta de venta de 3,731 acciones ordinarias con un valor de mercado agregado de $417,872. Las acciones son t铆tulos restringidos que se consolidaron el 08/07/2025 y fueron adquiridas como 肠辞尘辫别苍蝉补肠颈贸苍. El declarante tiene la intenci贸n de vender las acciones en o alrededor del 08/08/2025 en el NASDAQ a trav茅s de ETRADE FINANCIAL CORPORATION. La compa帽铆a muestra 60,658,809 acciones en circulaci贸n e informa 'Nothing to Report' respecto a valores vendidos en los 煤ltimos tres meses. El aviso incluye la declaraci贸n est谩ndar de que el vendedor desconoce cualquier informaci贸n material adversa no divulgada sobre el emisor.
Jazz Pharmaceuticals電� 鞝滌晥霅� 毵り皝鞚� 氤搓碃頃橂姅 Form 144毳� 鞝滌稖頄堨溂氅�, 3,731欤检潣 氤错喌欤茧ゼ 齑� 鞁滉皜 $417,872鞐� 毵り皝頃� 鞓堨爼鞚措澕瓿� 氤搓碃頄堨姷雼堧嫟. 頃措嫻 欤检嫕鞚� 08/07/2025鞐� 甓岆Μ臧� 頇曥爼霅� 鞝滍暅攵� 欤检嫕(restricted stock)鞙茧 氤挫儊鞙茧 旆摑霅橃棃鞀惦媹雼�. 鞝滌稖鞛愲姅 頃措嫻 欤检嫕鞚� 08/08/2025瓴� NASDAQ鞐愳劀 ETRADE FINANCIAL CORPORATION鞚� 韱淀暣 毵り皝頃� 瓿勴殟鞛呺媹雼�. 須岇偓電� 60,658,809欤检潣 氚滍枆欤检嫕鞚� 氤搓碃頃橂┌ 歆�雮� 3臧滌洈臧� 毵る弰霅� 歃濌秾鞐� 甏�頃挫劀電� 氤搓碃頃� 靷暛 鞐嗢潓鞚措澕瓿� 旮办灛頄堨姷雼堧嫟. 韱奠鞐愲姅 毵る弰鞚胳澊 氚滍枆須岇偓鞐� 甏�頃� 瓿店皽霅橃 鞎婌潃 欷戨寑頃� 攵堧Μ頃� 鞝曤炒毳� 鞎岅碃 鞛堨 鞎婋嫟電� 響滌 歆勳垹鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Jazz Pharmaceuticals a d茅pos茅 un Form 144 d茅clarant la vente propos茅e de 3,731 actions ordinaires pour une valeur marchande totale de $417,872. Les actions repr茅sentent des titres restreints qui sont devenus acquis le 08/07/2025 et ont 茅t茅 re莽us en tant que 谤茅尘耻苍茅谤补迟颈辞苍. Le d茅posant a l'intention de vendre les actions aux alentours du 08/08/2025 sur le NASDAQ via ETRADE FINANCIAL CORPORATION. La soci茅t茅 d茅clare 60,658,809 actions en circulation et indique 'Nothing to Report' pour les titres vendus au cours des trois derniers mois. L'avis inclut la mention standard selon laquelle le vendeur n'a connaissance d'aucune information d茅favorable mat茅rielle non divulgu茅e concernant l'茅metteur.
Jazz Pharmaceuticals reichte ein Form 144 ein und meldete den geplanten Verkauf von 3,731 Stammaktien mit einem gesamten Marktwert von $417,872. Die Aktien sind eingeschr盲nkte Aktien, die am 08/07/2025 unverfallbar geworden sind und als 痴别谤驳眉迟耻苍驳 erworben wurden. Der Einreicher beabsichtigt, die Aktien am oder um den 08/08/2025 an der NASDAQ 眉产别谤 ETRADE FINANCIAL CORPORATION zu ver盲u脽ern. Das Unternehmen gibt 60,658,809 ausstehende Aktien an und meldet 'Nothing to Report' f眉r in den letzten drei Monaten verkaufte Wertpapiere. Die Mitteilung enth盲lt die 眉bliche Zusicherung, dass dem Verk盲ufer keine nicht offengelegte, wesentliche nachteilige Information 眉产别谤 den Emittenten bekannt ist.
